Dr Oluwole Jegede joins Ethics Talk to discuss his article, coauthored with Drs Julio C. Nunes, Terence Tumenta, Carmen Black, and Joao P. DeAquino: “What Would Equitable Harm Reduction Look Like?”
Dr Elizabeth Salisbury-Afshar joins Ethics Talk to discuss her article, coauthored with Drs Catherine J. Livingston and Ricky N. Bluthenthal: “How Should Harm Reduction Be Included in Care Continua for Patients With Opioid Use Disorder?”
Dr Donald Egan joins Ethics Talk to discuss his article, coauthored with Drs Adriane M. dela Cruz, Sarah E. Baker, and John Z. Sadler: “When Are ‘Paraphernalia’ Critical Medical Supplies?”
Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020;22(11):E911-918. doi:
10.1001/amajethics.2020.911.
The financial generosity of the pharmaceutical industry to provide funding for medical education tempts a compromise of professional standards and ethics.
In April 2002, many pharmaceutical companies adopted PhRMA code, an attempt to self-regulate the pharmaceutical industry's marketing to physicians and other health care professionals.
A U.S. physician relates the culture shock he is experiencing working as an area medical officer in Eastern Africa for the U.S. Peace Corps in his latest online journal entry.
The authors of a recent journal article believe that most doctors and clinical trial sponsors would not object to changes in regulations requiring doctors to disclose financial incentives to their patients.